|Bid||0.00 x 900|
|Ask||0.00 x 1000|
|Day's Range||38.05 - 38.07|
|52 Week Range||31.73 - 43.06|
|PE Ratio (TTM)||N/A|
|Beta (3Y Monthly)||0.86|
|Expense Ratio (net)||0.63%|
PharmaMar (PHM.MC) announces that the International Association for the Study of Lung Cancer (IASLC) has released today the abstracts for presentation during the Conference that will take place from the 23rd to the 26th of September in Toronto (Canada). The abstract to be presented by PharmaMar shows Overall Survival (OS) data obtained from the Phase I/II Study of lurbinectedin in combination with doxorubicin for the treatment of relapsed small-cell lung cancer.
The SPDR S&P Retail ETF (XRT) , the largest retail-related exchange traded fund, jumped nearly 4.8% in August, extending its third-quarter gain to over 10%. The strength in the retail sector this year is a stark contrast in previous years when investors grew concerned over the future outlook of traditional brick-and-mortar stores in face of a rising competition from e-commerce or internet retailers. “Specifically, retail has been one of the best sectors to own in September, according to data from Schaeffer's Senior Quantitative Analyst Rocky White.
It’s been a great year for the retail sector with SPDR S&P Retail ETF (NYSEARCA:XRT), Invesco Dynamic Retail ETF (NYSEARCA:PMR) and VanEck Vectors Retail ETF (NYSEARCA:RTH) returning 18.5%, 12.7% and 12.3%, respectively, against 7.5% returns offered by SPDR S&P 500 ETF (NYSEARCA:SPY).
For retail ETF investors, it's a lesson in profitability as seen in the Invesco Dynamic Retail ETF (PMR), which reached a new 52-week high of $42.67 today. For this school year, retail shops are expecting a robust shopping season as multinational professional firm Deloitte is forecasting that this year's back-to-school spending will increase by 2.2 percent to $27.6 billion, with the average spending per household rising to $510 from $501 last year, including $112 on school supplies--up from $104 the previous year.
The Zacks Analyst Blog Highlights: SPDR S&P Retail, Amplify Online Retail, ProShares Online Retail, VanEck Vectors Retail and Invesco Dynamic Retail
As back-to-school season has entered its peak month, retailers are on the edge with initiatives to perk up sales. This is the second-busiest shopping season (mid July to mid September) after the Christmas holidays, with sales generally picking up in mid August.Source: Shutterstock
As summer vacation draws to a close, it’s back to pencils, books and teachers’ dirty looks for many students, which bodes well for retail ETFs looking to capitalize on a busy back-to-school shopping season. ...
If the U.S. is stuck in an escalating trade war, stocks and sector-related ETFs with the highest domestic sales exposure in the U.S. should begin to stand out. “If trade tensions continue to rise and new ...
MADRID , August 3, 2018 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to lurbinectedin for the treatment of small cell lung cancer (SCLC) S CLC is a ...
PharmaMar (PHM.MC) has today announced that the pivotal phase III trial ATLANTIS in relapsed small-cell lung cancer has reached the targeted number of 600 patients recruited. The ATLANTIS trial compared Lurbinectedin plus doxorubicin to physician's choice of either Topotecan or CAV (cyclophosphamide, adriamycin, vincristine) in a 1 to 1 randomization. The primary endpoint is overall survival, and based on expected number of events, top line data analysis will be available once 510 events occurs, around the end of 2019.
MADRID , July 27, 2018 /PRNewswire/ -- PharmaMar will receive an up-front payment of 2 million euros This agreement will replace the current agreement between PharmaMar and Swedish Orphan ...
MADRID , June 26, 2018 /PRNewswire/ -- PharmaMar regains all its rights for Zepsyre ® in Japan with immediate effec t and receives a payment of € 3,000, 000 from Chugai PharmaMar progresses in the clinical ...
MADRID , June 11, 2018 /PRNewswire/ -- PharmaMar (MCE: PHM) has announced today the signing of a commercialization and distribution license agreement with Pint Pharma International, S.A. for the marine-derived ...
It's not the end of brick-and-mortar retailing. Omnichannel retailing has been propelling the sector and should boost these ETFs.
The modelled data on overall survival of the statistical evaluation of the impact of crossover on the ADMYRE study were presented. After analyzing the impact of crossover, the registered overall survival with plitidepsin was 11.6 months against the 6.4 months of dexamethasone alone. PharmaMar (PHM.MC) has presented today how crossover has had an influence on the overall survival of the ADMYRE trial.
PharmaMar (PHM.MC) today announced new data on the recurrent small-cell lung cancer patients cohort of the phase II basket study with lurbinectedin as a single agent, will be presented at the American Society of Clinical Oncology (ASCO) annual meeting, being held from the 1st to the 5th of June in Chicago. Among these, small-cell lung cancer, recurrent after one chemotherapy prior line, began by recruiting 15 patients, and later increased to 100 after observing 5 responses in the first 15 patients.
What’s making small-cap retail attractive? There are a whole list of factors that have driven these stocks to levels that traditional value people and deep value people would look at. The valuations have been driven down primarily by a lack of ...
MADRID , May 29, 2018 /PRNewswire/ -- PharmaMar (MCE: PHM) has announced today that the Independent Data Monitoring Committee (IDMC) has notified the Company of its recommendation that the Phase III (ATLANTIS) ...